Compositions and methods of treatment of cancer
OwnerCynthia C. Bamdadinventor
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to compositions useful in the treatment or prevention of cancer, in some cases by limiting or preventing angiogenesis. Other compositions useful for the treatment or prevention of cancer or angiogenesis include homologs, analogs, derivatives, enantiomers or functionally equivalent compositions of the present invention. The present compositions can be packaged in kits. The present invention also relates to the use of compositions useful for the treatment of patients susceptible to or exhibiting symptoms characteristic of cancer, for example, patients with solid tumors.
Claims15
A composition, comprising a structure:
- 22
- wherein A1, A2, A3, and A4 are each independently selected from the group consisting of H and a halogen,
- Y1, Y2, Y3, R2 and R3 each independently comprise an atom,
- G1, G2, G3, G4, G5, and G6 each independently comprise an atom able to form at least three covalent bonds, and
- Ak comprises an alkyl.
A composition, comprising a structure:
- 23
- wherein A1, A2, A3, and A4 are each independently selected from the group consisting of H and a halogen,
- Y1, Y2, Y3, Y4, R2 and R3 each independently comprise an atom, and
- G1, G2, G3, G4, G5, and G6 each independently comprise an atom able to form at least three covalent bonds.
A composition, comprising a structure:
- 24
- wherein A1, A2, A3, and A4 are each independently selected from the group consisting of H and a halogen,
- Y1, Y2, Y3, Y4, R1 and R2 each independently comprise an atom,
- G1, G2, G3, G4, G5, and G6 each independently comprise an atom able to form at least three covalent bonds, and
- E comprises a sulfur atom.
A composition, comprising a structure:
- 25
- wherein A1, A2, A3, and A4 are each independently selected from the group consisting of H and a halogen,
- Y1, Y2, Y3, Y4, R1, R2, R11, R12, R13, R14, R15, R16, R17, and R18 each independently comprise an atom,
- G1, G2, G3, G4, G5, and G6 each independently comprise an atom able to form at least three covalent bonds, and
- J comprises a chemical bond or an atom.
A composition, comprising a structure:
- 26
- wherein A1, A2, A3, and A4 are each independently selected from the group consisting of H and a halogen,
- Y1, Y2, Y3, Y4, R1, R2, R11, R12, R13, R14, and R15 each independently comprise an atom, and
- G1, G2, G3, G4, G5, and G6 each independently comprise an atom able to form at least three covalent bonds.
A composition, comprising a structure:
- 27
- wherein R20 and R21 each independently comprise an atom,
- E comprises at least 2 cyclic groups, and
- Z comprises at least two fused cyclic structures;
- in combination with a pharmaceutically acceptable carrier.
A composition, comprising a structure:
- 28
- wherein Ak comprises a non-heteroatom alkyl group,
- R21, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, and R44 each independently comprise an atom, and
- J1 and J2 each independently comprise a chemical bond or an atom;
- in combination with a pharmaceutically acceptable carrier.
A composition, comprising a structure:
- 29
- wherein R11, R12, R13, R14, R15, R16, R17, R18, R50, and R51 each independently comprise an atom,
- G1, G2, G3, G4, and G5 each independently comprise an atom able to form at least three covalent bonds, and
- J comprises a chemical bond or an atom;
- in combination with a pharmaceutically acceptable carrier.
A composition, comprising a structure:
- 30
- wherein R11, R12, R13, R14, R15, and R50 each independently comprise an atom,
- G1, G2, G3, G4, and G5 each independently comprise an atom able to form at least three covalent bonds,
- Ak comprises an alkyl, and
- E comprises a sulfur atom;
- in combination with a pharmaceutically acceptable carrier.
A composition, comprising a structure:
- 31
- wherein R11, R12, R13, R14, R15, R50, R51, R52, and R53 each independently comprise an atom,
- G1, G2, G3, G4, G5, G6, G7, G8, and G9 each independently comprise an atom able to form at least three covalent bonds, and
- E comprises a sulfur atom;
- in combination with a pharmaceutically acceptable carrier.
A method, comprising:
- treating a human patient susceptible to or exhibiting a solid tumor, by administering to the patient a therapeutically effective amount of a composition that inhibits the tumor by inhibiting angiogenesis, comprising:
- 32
- wherein A1, A2, A3, and A4 are each independently selected from the group consisting of H and a halogen,
- Y1, Y2, Y3, Y4, R1, R2 and R3 each independently comprise an atom,
- G1, G2, G3, G4, G5, and G6 each independently comprise an atom able to form at least three covalent bonds, and
- the patient is not otherwise indicated for treatment with the composition.
Dependencies are inferred from the claim text.